EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Screening the MMV Pathogen Box reveals the mitochondrial bc1-complex as a drug target in mature Toxoplasma gondii bradyzoites

Deborah Maus, Elyzana Putrianti, Tobias Hoffmann, Michael Laue, Frank Seeber, Martin Blume iD

eLife · 2026

DOI: 10.7554/elife.102511 ↗

Kurz gefasst

Fachartikel in der Zeitschrift eLife, 2026. Verfasst von Deborah Maus und 5 weiteren Autor:innen. Beteiligte Einrichtung: P 6: Metabolism of Microbial Pathogens, Robert Koch Institute, Berlin, Germany. Hauptthemen laut MEDLINE: Toxoplasma, Electron Transport Complex III, Antiprotozoal Agents, Mitochondria. Die Arbeit nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Federal Ministry of Education and Research, Robert Koch Institut.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The apicomplexan parasite Toxoplasma gondii infects 25–30% of the global human population and can cause life-threatening diseases in immunocompromised patients. The chronically infectious forms of the parasite, bradyzoites, persist within cysts in brain and muscle tissue, and are responsible for its transmission and remission of the disease. Currently available treatment options are very limited and are only effective against the fast-replicating tachyzoites, but fail to eradicate the chronic stages of T. gondii . The cause of these treatment failures remains unclear. Here, we utilized our recently developed human myotube-based culture model to screen compounds from the MMV Pathogen Box against pan-resistant in vitro bradyzoites, and identified multiple compounds with simultaneous activity against tachyzoites and bradyzoites. Stable isotope-resolved metabolic profiling on tachyzoites and bradyzoites identified the mitochondrial bc 1 -complex as a target of bradyzocidal compounds and defined their metabolic impacts on both parasite forms. Our data suggest that mature bradyzoites rely on mitochondrial ATP production.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ToxoplasmaElectron Transport Complex IIIAntiprotozoal AgentsMitochondriaHumansAdenosine TriphosphateDrug Evaluation, PreclinicalMuscle Fibers, Skeletal

Stichwörter der Autor:innen

Toxoplasma gondiibiochemistrybradyzoitechemical biologychronic infectioncompound screenenergy metabolisminfectious diseasemetabolomicsmicrobiology

Substanzen

Electron Transport Complex IIIAntiprotozoal AgentsAdenosine Triphosphate

Autor:innen und Institutionen

  • P 6: Metabolism of Microbial Pathogens, Robert Koch Institute, Berlin, Germany.
  • ZBS 4: Advanced Light and Electron Microscopy, Centre for Biological Threats and Special Pathogens 4, Robert Koch-Institute, Berlin, Germany.
  • FG 16: Mycotic and Parasitic Agents and Mycobacteria, Robert Koch Institute, Berlin, Germany.

ORCID-Profile: Martin Blume

Förderung

  • Federal Ministry of Education and Research
  • Robert Koch Institut

Zitieren

APA

Maus, D., Putrianti, E., Hoffmann, T., Laue, M., Seeber, F., & Blume, M. (2026). Screening the MMV Pathogen Box reveals the mitochondrial bc1-complex as a drug target in mature Toxoplasma gondii bradyzoites. eLife. https://doi.org/10.7554/elife.102511

Vancouver

Maus D, Putrianti E, Hoffmann T, Laue M, Seeber F, Blume M. Screening the MMV Pathogen Box reveals the mitochondrial bc1-complex as a drug target in mature Toxoplasma gondii bradyzoites. eLife. 2026. doi:10.7554/elife.102511

BibTeX
@article{Maus2026,
  author = {Maus, Deborah and Putrianti, Elyzana and Hoffmann, Tobias and Laue, Michael and Seeber, Frank and Blume, Martin},
  title = {Screening the MMV Pathogen Box reveals the mitochondrial bc1-complex as a drug target in mature Toxoplasma gondii bradyzoites},
  journal = {eLife},
  year = {2026},
  doi = {10.7554/elife.102511}
}
Kostenlos starten →